- $1.12bn
- $1.05bn
- $399.25m
- 83
- 42
- 42
- 56
Annual income statement for AtriCure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 231 | 207 | 274 | 330 | 399 |
| Cost of Revenue | |||||
| Gross Profit | 170 | 149 | 206 | 246 | 300 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 264 | 251 | 219 | 373 | 426 |
| Operating Profit | -33.1 | -44.2 | 55.2 | -42.7 | -26.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -35 | -48 | 50.4 | -46.2 | -29.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -35.2 | -48.2 | 50.2 | -46.5 | -30.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -35.2 | -48.2 | 50.2 | -46.5 | -30.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -35.2 | -48.2 | 50.2 | -46.5 | -30.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.868 | -1.08 | 2.87 | -1.02 | -0.657 |